ErbB/HER receptor family in breast cancer - The more we search the more we learn

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 1020-1021

  Karamouzis, M V ^a,b   Konstantinopoulos, P A ^a,c   Papavassiliou, A G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; DIMERIZATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; LETTER; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIGANDS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION;

EID: 43049097534     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn061     Document Type: Letter

References (12)

1. Revillion F, Lhotellier V, Hornez L et al. ERBb/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 73-80.
2. Hudis GA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
3. Karamouzis MV, Argiris A, Grandis JR. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA 2007; 298: 90-182.
4. Karamouzis MV, Badra FA, Papavassiliou AG. Breast cancer: The upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007; 39: 851-856.
5. Ritter CA, Perez-Torres M, Rinehart C et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 2007; 13: 4657-4659.
6. Perez SA, Karamouzis MV, Skados DV et al. CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 2007; 13: 2714-2721.
7. Ali SM, Esteva FJ, Fornier M et al. Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. J Clin Oncol 2006; 24(18S): 500.
8. Smith BL, Chin D, Maltzman W et al. The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br J Cancer 2004; 91: 1190-1194.
9. Wollf AC, Hammond MEH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
10. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Trastuzumab - Mechanism of action and use. N Engl J Med 2007; 357: 1664.
11. de Alava E, Ocana A, Abad M et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. J Clin Oncol 2007; 25: 2656-2663.
12. Menendez JA, Mehmi I, Lupu R. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression. J Clin Oncol 2006; 24: 3735-3746.